Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $11.00.
A number of equities research analysts have weighed in on the stock. Morgan Stanley lifted their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, June 21st. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, July 18th. They set an “outperform” rating and a $14.00 target price on the stock.
View Our Latest Stock Analysis on CNTA
Institutional Investors Weigh In On Centessa Pharmaceuticals
Centessa Pharmaceuticals Price Performance
Shares of NASDAQ:CNTA opened at $11.40 on Friday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -8.03 and a beta of 1.40. The business has a 50 day moving average price of $9.50 and a 200 day moving average price of $9.75. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a twelve month low of $5.15 and a twelve month high of $12.45.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. Research analysts predict that Centessa Pharmaceuticals will post -1.62 earnings per share for the current year.
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Further Reading
- Five stocks we like better than Centessa Pharmaceuticals
- Manufacturing Stocks Investing
- Owens-Corning Stock: Good Value or Recession Red Flag?
- What is a buyback in stocks? A comprehensive guide for investors
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- Using the MarketBeat Dividend Yield Calculator
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.